FLUONIR Information

FLUONIR is a French biotech company founded in Dijon in March 2026, developing NIR-II fluorescent imaging agents for preclinical research and fluorescence-guided surgery (FGS). Our proprietary WAZABY platform is based on water-soluble fluorophores emitting in the second near-infrared window (NIR-II, 1,000–1,700 nm). Compared with conventional NIR-I imaging, NIR-II offers the potential to reduce tissue autofluorescence and light scattering, enabling deeper tissue imaging, improved contrast and sharper images. Our fluorophores are designed to be chemically and photochemically stable, easy to produce and compatible with bioconjugation to biological targeting agents, including antibodies. This modular approach enables the development of customizable imaging probes tailored to specific biological targets. 🔬 Our activities focus on two complementary areas: • Preclinical research: customized NIR-II imaging probes and solutions for cell imaging, in vivo studies and biomarker validation. • Fluorescence-guided surgery: developing our lead candidate, WAZABY-1000-panitumumab, which combines our proprietary fluorophore with an anti-EGFR antibody, initially targeting EGFR-positive head and neck cancers. Built on more than ten years of academic research and scientific collaborations between Dijon and Grenoble, FLUONIR aims to bridge the gap between laboratory discoveries and medical applications. Our technology is currently in preclinical development, with the ambition of helping surgeons better visualize tumors and guide surgical procedures in the future. 📍 Based in Dijon, France, FLUONIR welcomes scientific, clinical and industry collaborations.